

# INDUSTRIAL BIOTECHNOLOGY: PROPELLING A BIO-BASED ECONOMY


CME ACS NY Luncheon/Webcast • April 6, 2017 • Penn Club

## Abstract

Biotechnology has become part of the mosaic of key technological enablers to strategic industrial growth. This presentation will discuss the insights of the leader of industrial biotechnology at the Biotechnology Innovation Organization (BIO), a trade association that represents more than 900 biotechnology companies, academic institutions, and state biotechnology centers across the United States and in more than 30 other nations.

Industrial biotechnology is a key tool in developing bio-based economies the world over. The sector has evolved from being focused on enzyme production in the early days to advanced biofuels production and now a broad array of industrial and consumer products. In recent years there has been an explosion of commercialization activity in the space around renewable chemical platforms. This includes well known bulk chemicals, fine chemicals, food ingredients and flavorings. This growth has come about partly because of government support, advances in technology, and demand for more renewable and sustainable processes. This Presentation will review the current state of the bio-based economy and industrial biotech in the U.S. and beyond.

Join our discussion on industrial biotechnology and on how with the insights of an industry thought leader you can realize strategic and operating value.



**Speaker:** Brent Erickson is executive vice president in charge of the Industrial and Environmental Section at the Biotechnology Innovation Organization (BIO).

Mr. Erickson holds a B.S. in Biology and an M.A. in International Studies. After completing graduate school Mr. Erickson joined the staff of United States Senator and Republican Whip Alan K. Simpson (R-WY) as a legislative assistant handling defense, energy, and environmental issues. In 1993, Mr. Erickson was promoted to legislative director.

In 1996, Mr. Erickson joined the American Petroleum Institute (API) as a Washington representative where he directed government relations efforts on energy and environmental issues. Mr. Erickson joined the Biotechnology Industry Organization (BIO) in 2000.

In 2001, Mr. Erickson was elected as vice-chair of the Organization for Economic Cooperation and Development's Task Force on Biotechnology for Sustainable Industrial Development, a position he held until 2005. In 2005 he was named consulting editor of the journal Industrial Biotechnology a post he continues to hold today.



## Event Schedule

### Location:

Penn Club  
30 W 44th Street, NYC

### Event Times: (ET)

11:15 am - 12:00 noon  
Registration and  
Networking

12 noon - 1 pm Luncheon  
1 pm - 2 pm Talk - Webcast

### Luncheon Fees

\$120 for non-members

\$90 for members

Check for Early-bird savings

**Webcast** : \$30. Free webcast  
recording for ACS members



## CME Board

### Chair

Charles Brumlik

### Vice Chair

Guy Penard

### Program Chair

James Weatherall

### Secretary

Adam Closson

### Treasurer

Karin Bartels

### Directors

Neil Burns

David J. Deutsch

Brian Orkin

Paul Pospisil

## In Partnership with



CME ACS NY Luncheon/Webcast • April 6, 2017 • Penn Club



**NEW YORK  
BIO**

**Nathan Tinker** Nathan Tinker has been Executive Director of New York BIO since 2007. He has more than 20 years of experience in working with both global and emerging technology companies. Prior to joining NYBIO, he served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as the Director of the Nanotechnology and Biotechnology Practice at Antenna Group. Dr. Tinker was Co-Founder and Executive Vice President of the NanoBusiness Alliance. He began his career in market research serving such clients as Apple, Sprint, Cantor Fitzgerald, DaimlerChrysler, Yahoo! and CSX. Dr. Tinker is in the advisory boards of Physicians Interactive Holdings, Viral Genetics, Versilant Technologies and the Nanotechnology Commercialization Association.



 **KORN FERRY**

**Paul Pospisil** is a Senior Client Partner, Global Life Sciences at KornFerry. His primary focus is to assist biotechnology and biopharmaceutical companies in recruiting for positions such as chief executive officer, chief business officer, head of research and development and other key executives. With over fifteen years in the industry as a successful executive and investor, Dr. Pospisil brings a thoughtful perspective to executive search, shaped by a breadth of experiences in company building, operational leadership and board functions from start-up, growth to mature companies. Prior to joining Korn Ferry, Dr. Pospisil was a co-founder and managing partner of both Aduro Capital LLC, and Aduro Partners LLC. He has worked at Atlas Venture, Millennium Pharmaceuticals and Altus Biologics. Dr. Pospisil holds a PhD in organic chemistry from Harvard University and a bachelor's degree in biochemistry from NYU. He attended Harvard Business School's Program for Management Development (PMD).

ACS NY Section  
**CMSE**

In Partnership with

**NEW YORK  
BIO**